367 related articles for article (PubMed ID: 34363425)
1. Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run.
van Veelen A; van Geel R; Schoufs R; de Beer Y; Stolk LM; Hendriks LEL; Croes S
Biomed Chromatogr; 2021 Dec; 35(12):e5224. PubMed ID: 34363425
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer.
Zhou L; Wang S; Chen M; Huang S; Zhang M; Bao W; Bao A; Zhang P; Guo H; Liu Z; Xie G; Gao J; Wu Z; Lou Y; Fan G
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1175():122752. PubMed ID: 33991955
[TBL] [Abstract][Full Text] [Related]
3. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
4. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib.
Veerman GDM; Lam MH; Mathijssen RHJ; Koolen SLW; de Bruijn P
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Apr; 1113():37-44. PubMed ID: 30889498
[TBL] [Abstract][Full Text] [Related]
5. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Mukai Y; Wakamoto A; Hatsuyama T; Yoshida T; Sato H; Fujita A; Inotsume N; Toda T
Ther Drug Monit; 2021 Dec; 43(6):772-779. PubMed ID: 33871406
[TBL] [Abstract][Full Text] [Related]
6. Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results.
van Veelen A; van Geel R; de Beer Y; Dingemans AM; Stolk L; Ter Heine R; de Vries F; Croes S
Biomed Chromatogr; 2020 Apr; 34(4):e4771. PubMed ID: 31808583
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasma.
Gulikers JL; van Veelen AJ; Sinkiewicz EMJ; de Beer YM; Slikkerveer M; Stolk LML; Tjan-Heijnen VCG; Hendriks LEL; Croes S; van Geel RMJM
Biomed Chromatogr; 2023 Jun; 37(6):e5628. PubMed ID: 36941218
[TBL] [Abstract][Full Text] [Related]
8. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous online SPE-HPLC-MS/MS quantification of gefitinib, osimertinib and icotinib in dried plasma spots: Application to therapeutic drug monitoring in patients with non-small cell lung cancer.
Jia M; Wu Z; Shi W; Wang S; Huang X; Zhang M; Bao W; Bao A; Zhang P; Ding F; Xie G; Lou Y; Fan G
J Pharm Biomed Anal; 2023 May; 228():115275. PubMed ID: 36871365
[TBL] [Abstract][Full Text] [Related]
10. An UPLC-MS/MS method for the quantitation of alectinib in rat plasma.
Huang XX; Li YX; Li XY; Hu XX; Tang PF; Hu GX
J Pharm Biomed Anal; 2017 Jan; 132():227-231. PubMed ID: 27768922
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Xiong X; Zhang Y; Wang Z; Zhou C; Yang P; Du X; Yang L; Liu W
Clin Chim Acta; 2022 Feb; 527():1-10. PubMed ID: 34999058
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.
Huynh HH; Pressiat C; Sauvageon H; Madelaine I; Maslanka P; Lebbé C; Thieblemont C; Goldwirt L; Mourah S
Ther Drug Monit; 2017 Feb; 39(1):43-54. PubMed ID: 27861317
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a novel LC-MS/MS method for simultaneous quantitative determination of tyrosine kinase inhibitors in human plasma.
Lou Y; Qin H; Hu Q; Chai Y; Zhou H; Chen M; Wang Q; Huang P; Gu J; Zhang Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Oct; 1208():123394. PubMed ID: 35932695
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC-MS/MS method and its application to human microsomal metabolic stability study.
Ezzeldin E; Iqbal M; Herqash RN; ElNahhas T
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1136():121851. PubMed ID: 31812004
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of dacomitinib and its major metabolite, O-desmethyl dacomitinib in human plasma by LC-MS/MS and its application to clinical testing in patients with non-small cell lung cancer.
Feng X; Ding Y; Zhang P; Fu Q; Zhang L; Zheng H
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122940. PubMed ID: 34564058
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry.
Ni MW; Zhou J; Li H; Chen W; Mou HZ; Zheng ZG
Bioanalysis; 2017 Jun; 9(12):925-935. PubMed ID: 28617069
[TBL] [Abstract][Full Text] [Related]
18. Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).
Roberts MS; Turner DC; Broniscer A; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jun; 960():151-7. PubMed ID: 24811158
[TBL] [Abstract][Full Text] [Related]
19. Determination of intracellular anlotinib, osimertinib, afatinib and gefitinib accumulations in human brain microvascular endothelial cells by liquid chromatography/tandem mass spectrometry.
Ma Z; Lu S; Zhou H; Zhang S; Wang Y; Lin N
Rapid Commun Mass Spectrom; 2021 Jan; 35(1):e8955. PubMed ID: 32990383
[TBL] [Abstract][Full Text] [Related]
20. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
Lankheet NA; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH; Huitema AD
Biomed Chromatogr; 2013 Apr; 27(4):466-76. PubMed ID: 22987603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
